Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SINO BIOPHARMACEUTICAL (01177.HK)'s Vetricotobat Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Phase III Clinical Trial
Recommend 8 Positive 12 Negative 5 |
||||
|
||||
|
SINO BIOPHARMACEUTICAL (01177.HK) announced that Vetricotobat Monoclonal Antibody (CLDN18.2 ADC), a Class 1 innovative drug independently developed by Lixin Pharmaceutical, a wholly-owned subsidiary of the Group, is undergoing a Phase III pivotal clinical trial (LM302-03-201) in combination with a PD-1 monoclonal antibody as first-line treatment for patients with CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (GC/GEJ). The first patient has been successfully enrolled. This study is the second Phase III clinical trial conducted for LM-302 and is also the worlds first Phase III clinical trial of a CLDN18.2 ADC therapy using a chemotherapy-free regimen for first-line treatment of gastric cancer. (sl/u) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
